Clinical Trial Search

Primary: Radiographic Progression-Free Survival (rPFS) — 8.0; 3.7 months — p=<0.0001

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…

Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants

Primary: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 — 14.0; 14.0 days — p=0.7414

Primary: A Change in the Autism Treatment Evaluation Checklist (ATEC) Total Score Compared to Baseline. — -12.122; -11.427 percentage change from baseline score — p=0.784

Primary: Perceived Self-efficacy for Condom Use — 13.00; 12.48 summation score

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1; 1 Participants

Primary: Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population) — 7.4; 5.7 Months — p=0.0010

Primary: Agreement of Intraocular Pressure — 0.3 mmHg

Primary: Buprenorphine Pharmacokinetics

Primary: Number of Participants With Adequacy of Suppression of Estradiol (E2) as Assessed by Estradiol Level Below 40 pg/mL — 6; 7; 5; 12 Participants

Primary: The Number of Participants With an Objective Tumor Response Rate — 3 participants

Primary: Nausea Scale — 8; 9; 6; 6 Participants

Primary: Subjective Ratings for Lens Handling for Lens Insertion — 9.3; 9.2 units on a scale

Primary: Number of Participants With Serious Adverse Events — 0 Participants